Pharma / Biotech

AbstractActivity and pharmacokinetics of a praziquantel crystalline polymorph in the Schistosoma mansoni mouse model.

Related Articles

AbstractActivity and pharmacokinetics of a praziquantel crystalline polymorph in the Schistosoma mansoni mouse model.

Eur J Pharm Biopharm. 2019 Jun 29;:

Authors: Lombardo FC, Perissutti B, Keiser J

Abstract
Schistosomiasis is a global disease of significant public health relevance. Only one racemic drug, praziquantel, characterized by low bioavailability low water solubility and extensive first pass metabolism, is currently available. We studied a new praziquantel formulation (polymorph B), which is based on a racemic praziquantel crystalline polymorph (TELCEU01). It’s in vitro activity was tested on newly transformed schistosomula (NTS) and adult Schistosoma mansoni In vivo studies were conducted in mice harboring chronic S. mansoni infections. Pharmacokinetic PK profiles of R- and S-praziquantel and R- S- polymorph B following oral administration with both formulations were generated by sampling mice at 30, 60, 240 min and 24 hours post-treatment, followed by LC-MS/MS analysis. PK parameters were calculated using a non-compartmental analysis with a linear trapezoidal model. In vitro, commercial praziquantel and the polymorph B performed similarly on both NTS (IC50 = 2.58 and 2.40 µg/mL at 72 h) and adults (IC50 = 0.05 and 0.07 µg/mL at 72 h). Praziquantel showed higher in vivo efficacy with an ED50 of 58.75 mg/kg compared to an ED50 of 122.61 mg/kg for the polymorph B. The PK profiles of the two drugs exhibited differences: R-praziquantel showed an overall 40% higher area under the plasma drug concentration-time curve (AUC0→24) (R-praziquantel = 3.42; R-polymorph B = 2.05 h*µg/mL) and an overall 30% lower apparent clearance (Cl/F) (R-praziquantel = 70.68 and R-polymorph B = 97.63 (mg)/(µg/mL)/h). Despite the lack of improved activity and PK properties of polymorph B, here presented, against S. mansoni, research on pharmaceutical polymorphism remains a valid and cost-effective option for the development of new praziquantel formulations with enhanced properties such as increased solubility and/or dissolution.

PMID: 31265895 [PubMed – as supplied by publisher]

Source link

Related posts

VANCOMYCIN HYDROCHLORIDE Injection, Powder, Lyophilized, For Solution [Fresenius Kabi, LLC]

Newsemia

Effect of feeding on the pharmacokinetics of vilazodone in dogs.

Newsemia

ULTIMATE SHEER SPF 55 BODY (Avobenzone 3.00% Homosalate 15.00% Octisalate 5.00% Octocrylene 2.75% Oxybenzone 6.00%) Spray [TopCo]

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World